Literature DB >> 8358406

A double-blind controlled study of methylphenidate treatment in closed head injury.

T J Speech1, S M Rao, D C Osmon, L T Sperry.   

Abstract

Closed head injuries (CHI) may produce permanent, disabling changes in cognitive functions and social behaviour. Recent clinical case reports have suggested that stimulant medications may improve neurobehavioural functioning in CHI patients. In the present study, we evaluated the effects of methylphenidate (0.3 mg/kg b.i.d.) in 12 chronic CHI patients (14 to 108 months post-injury) using a double-blind, placebo-controlled, randomized, crossover design. Outcome measures consisted of cognitive tests of attention, learning and cognitive processing speed. In addition, a rating scale was completed by a close friend or relative to assess social behaviour. No significant differences were found between drug and placebo conditions on any of the neurobehavioural measures. These data do not support the clinical use of methylphenidate in the treatment of CHI patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358406     DOI: 10.3109/02699059309034959

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  15 in total

Review 1.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

Review 2.  Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.

Authors:  Susan E Hardy
Journal:  Am J Geriatr Pharmacother       Date:  2009-02

3.  Cognitive Impairment Following Traumatic Brain Injury.

Authors:  David B. Arciniegas; Kerri Held; Peter Wagner
Journal:  Curr Treat Options Neurol       Date:  2002-01       Impact factor: 3.598

Review 4.  Stimulant drugs.

Authors:  P J Santosh; E Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 5.  Common psychiatric syndromes and pharmacologic treatments of traumatic brain injury.

Authors:  L A Labbate; D L Warden
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

Review 6.  Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Authors:  Ramon Diaz-Arrastia; Patrick M Kochanek; Peter Bergold; Kimbra Kenney; Christine E Marx; Col Jamie B Grimes; L T C Yince Loh; L T C Gina E Adam; Devon Oskvig; Kenneth C Curley; Wanda Salzer
Journal:  J Neurotrauma       Date:  2014-01-15       Impact factor: 5.269

Review 7.  Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis.

Authors:  James W Bales; Amy K Wagner; Anthony E Kline; C Edward Dixon
Journal:  Neurosci Biobehav Rev       Date:  2009-04-01       Impact factor: 8.989

8.  Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia.

Authors:  Shibley Rahman; Trevor W Robbins; John R Hodges; Mitul A Mehta; Peter J Nestor; Luke Clark; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853

9.  Neuropsychiatric Aspects of Traumatic Brain Injury.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-03       Impact factor: 3.972

10.  Frontal Traumatic Brain Injury in Rats Causes Long-Lasting Impairments in Impulse Control That Are Differentially Sensitive to Pharmacotherapeutics and Associated with Chronic Neuroinflammation.

Authors:  Cole Vonder Haar; Frederick C W Lam; Wendy K Adams; Lara-Kirstie Riparip; Sukhbir Kaur; Michael Muthukrishna; Susanna Rosi; Catharine A Winstanley
Journal:  ACS Chem Neurosci       Date:  2016-08-30       Impact factor: 5.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.